Rifaximin Versus Lactulose in Renal Failure
| Status: | Completed |
|---|---|
| Conditions: | Renal Impairment / Chronic Kidney Disease, Gastrointestinal |
| Therapuetic Areas: | Gastroenterology, Nephrology / Urology |
| Healthy: | No |
| Age Range: | 18 - 65 |
| Updated: | 4/2/2016 |
| Start Date: | June 2008 |
| End Date: | July 2009 |
| Contact: | Samuel Sigal, MD |
| Email: | shs2015@nyp.org |
| Phone: | 212-746-4129 |
A Randomized Comparison of Rifaximin Versus Lactulose in Hospitalized Cirrhotic Patients With Progressive Renal Failure
The purpose of this study is to evaluate patients with cirrhosis of the liver and renal
failure and determine if the administration of rifaximin as compared to lactulose is
associated with less frequent and/or slower progression to severe hepatic encephalopathy. If
one is associated with lower blood ammonia levels. And, if one is associated with lower
breath hydrogen and methane levels.
failure and determine if the administration of rifaximin as compared to lactulose is
associated with less frequent and/or slower progression to severe hepatic encephalopathy. If
one is associated with lower blood ammonia levels. And, if one is associated with lower
breath hydrogen and methane levels.
Inclusion Criteria:
- cirrhosis of liver of any etiology
- progressive renal failure
- stage 0-2 hepatic encephalopathy
Exclusion Criteria:
- pregnant women
We found this trial at
1
site
Click here to add this to my saved trials
